Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Arrowhead Pharmaceuticals Inc(ARWR)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ARWR
10/19/2026: ARWR (2-star) is currently NOT-A-BUY. Pass it for now.
Arrowhead Pharmaceuticals is a clinical-stage biotechnology company that utilizes proprietary RNA interference technology to silence genes associated with serious diseases. Its business model centers on developing a versatile drug platform and forming high-value partnerships with major pharmaceutical companies to fund and commercialize its pipeline. The company’s primary opportunity lies in the potential for its TRiM technology to create breakthrough therapies in cardiometabolic and pulmonary spaces. However, investors face significant risks, including the inherent uncertainty of clinical trials, potential competition, and a high burn rate. The stock may suit growth-oriented investors with a high risk tolerance who are looking for long-term potential in genetic medicine.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers high growth potential linked to the success of its innovative RNAi technology platform. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may find opportunity during clinical trial readouts or major partnership announcements. |
| Value investor | Weak fit | The stock lacks stable earnings or dividends, making it difficult to value using traditional metrics. |
| Dividend investor | Weak fit | The company does not pay dividends and prioritizes R&D spending. |
| Low-risk investor | Weak fit | High clinical development risk and price volatility make this unsuitable for risk-averse investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is highly sensitive to clinical trial outcomes and partnership news. |
| Valuation risk | High | Valuations are speculative, based on long-term drug development potential rather than current profits. |
| Competition risk (RNAi/Oligonucleotide) | Medium / high | The sector is crowded with well-funded competitors like Alnylam and Ionis. |
| Business quality | Medium | While the technology is highly regarded, the company is still in the process of transitioning to a commercial business. |
| Dividend income | Low / none | Income investors will not find yield here as all cash is used for development. |
| Execution risk | Medium / high | The company must successfully navigate complex regulatory paths to bring drugs to market. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -18.61% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/19/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.90B USD | Price to earnings Ratio - | 1Y Target Price 107.71 |
Price to earnings Ratio - | 1Y Target Price 107.71 | ||
Volume (30-day avg) 2.3M shares | Beta 1.3 | 52 Weeks Range 36.73 - 95.49 | Updated Date 10/18/2026 |
52 Weeks Range 36.73 - 95.49 | Updated Date 10/18/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.28 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Strategic Collaborations | Upfront payments, development milestones, and royalty agreements with big pharma partners. | The company makes money by licensing its drug platform to larger partners who help pay for and commercialize the drugs. |
Valuation
Trailing PE - | Forward PE 111.11 | Enterprise Value 8.84B | Price to Sales(TTM) 11.79 |
Enterprise Value 8.84B | Price to Sales(TTM) 11.79 | ||
Enterprise Value to Revenue 13.37 | Enterprise Value to EBITDA 27.85 | Shares Outstanding 141.25M | Shares Floating 122.45M |
Shares Outstanding 141.25M | Shares Floating 122.45M | ||
Percent Insiders 3.66 | Percent Institutions 85.25 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.